Developer docs
API playgroundTry for free, no card

Search company profiles

Racura Oncology

Full company profile

uuid00yhod9

Namestring
Racura Oncology
Legal namestring
Racura Oncology Limited
Company typeenum
Public
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, clinical stage biopharmaceutical, cancer therapeutics research, cardioprotective anticancer agents, small molecule oncology
Industry1 code
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Misc Health & Allied Services, Nec8090
Product category
Oncology Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development & Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. The company is developing (E,E)-bisantrene (RC220) for multiple oncology indications. Revenue is expected upon regulatory approval and commercialization of the drug candidate.

racuraoncology.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as an anticancer therapy with dual anticancer and cardioprotective properties. The lead asset targets multiple oncology indications including acute myeloid leukemia (AML), EGFR-mutated non-small cell lung cancer (NSCLC), and solid tumours in combination with doxorubicin, through Phase 1, Phase 1a/b, and Phase 3 clinical programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 46% complete response rate in relapsed/refractory AML across 10 monotherapy studies with 146 patients
+3 more records
Product overview1 text field

Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as a targeted cancer therapy with unique cardioprotective properties. The company's product portfolio centers on RC220 as the lead asset, which is being advanced through multiple clinical programs: Phase 3 in acute myeloid leukemia (EMILI-3), Phase 1a/b in EGFR-mutated non-small cell lung cancer (HARNESS-1), and Phase 1 in solid tumours in combination with doxorubicin (CPACS). The company also maintains the original bisantrene formulation (RC110) with published Phase 2 clinical data. All formulations leverage the drug's mechanism of action involving G4-DNA and RNA binding to silence the MYC cancer growth regulator.

Product and service2 records
1RC220
CategoryOncology Pharmaceuticals
Description

Proprietary reformulated version of (E,E)-bisantrene designed to enable peripheral and central intravenous administration while maintaining pharmacokinetics and anticancer activity. Lead drug candidate with dual anticancer and cardioprotective properties for AML, EGFRm NSCLC, and solid tumours in combination with doxorubicin.

2Cardioprotection Blood Test
CategoryCompanion Diagnostics
Description

Novel blood-based molecular test designed to assess the cardioprotective effects of lead drug candidate RC220 in cancer patients undergoing chemotherapy.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Astex
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Astex, a leading precision medicine company, as part of Racura's global scientific and medical partnerships network.

racuraoncology.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive licensing agreement with City of Hope for bisantrene development. City of Hope is a renowned cancer research and treatment institution.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with MD Anderson, one of the world's most respected cancer centers, as part of global partnerships to advance bisantrene.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Sheba Medical Center in Israel, where investigator-sponsored bisantrene trials in AML were conducted under Professor Arnon Nagler.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with University of North Carolina School of Medicine as part of Racura's global scientific and medical partnerships network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with University of Wollongong for bisantrene research and development. Professor Michael Kelso, VP of Research, is from this university.

7University of Newcastle
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with University of Newcastle as part of Racura's collaboration network for scientific research.

racuraoncology.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Manufacturing partnership with Ardena Holding NV to provide additional current Good Manufacturing Practice (cGMP) manufacturing for bisantrene.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Purdue University for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Emory University as part of Racura's scientific partnerships network to advance understanding of bisantrene.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Contract Research Organisation (CRO) appointed to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Associate Professor Erin Howden from the Baker Heart and Diabetes Institute joined Racura's Scientific Advisory Board to provide expertise on cardiometabolic effects of chemotherapy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Australian clinical-stage oncology company developing small-molecule drugs for brain cancers and other solid tumors. Comparable as a small ASX-listed biotech with an oncology pipeline.

TypeRegional player
Description

Australian clinical-stage immuno-oncology company developing B-cell vaccines and oncolytic virotherapy. Comparable as a small ASX-listed oncology biotech advancing multiple clinical programs.

TypeBroad incumbent
Description

Global pharmaceutical company with venetoclax (Venclexta), a leading AML therapy. Represents the established competitive standard-of-care that any new AML entrant must address.

TypeEmerging player
Description

US clinical-stage company developing targeted radiotherapies for AML and other hematologic malignancies. Comparable as a small-cap AML-focused developer at a similar clinical stage to Racura.

TypeBroad incumbent
Description

Global pharmaceutical company with significant AML franchise (Tibsovo, idhifa) and oncology pipeline. Represents the established competitive landscape in hematologic oncology.

TypeEmerging player
Description

Developer of small molecules targeting G-quadruplex (G4) DNA structures and MYC oncogene regulation. Directly comparable to Racura's G4-DNA/MYC mechanism of action for (E,E)-bisantrene, though at a different stage of development.

TypeDirect peer
Description

Australian clinical-stage oncology company developing small-molecule therapeutics. Comparable to Racura as a similarly small ASX-listed biotech pursuing oncology indications with limited commercial revenue.

TypeRegional player
Description

Australia-based clinical-stage developer of oncology therapeutics. Geographic and stage peer to Racura, though Opthea focuses on ophthalmology-related VEGF therapies rather than cytotoxic chemotherapy.

TypeBroad incumbent
Description

Global pharmaceutical company with established AML and oncology franchises, including gilteritinib. Sets the competitive bar for AML drug approvals and reimbursement.

TypeDirect peer
Description

Clinical-stage oncology company developing small-molecule drugs with a primary focus on acute myeloid leukemia. Directly comparable to Racura's AML-led development strategy with RC220.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Racura Oncology

Oncology Pharmaceuticalsracuraoncology.com

Racura Oncology firmographics

Firmographics
Name
Racura Oncology
Legal name
Racura Oncology Limited
Website
https://racuraoncology.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Racura Oncology industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oncology drug development
  • Clinical stage biopharmaceutical
  • Cancer therapeutics research
  • Cardioprotective anticancer agents
  • Small molecule oncology

Where Racura Oncology is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Racura Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development & Commercialization: Pre-revenue clinical-stage biopharmaceutical company. The company is developing (E,E)-bisantrene (RC220) for multiple oncology indications. Revenue is expected upon regulatory approval and commercialization of the drug candidate.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Racura Oncology product offering

Product offering

Core offering

Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as an anticancer therapy with dual anticancer and cardioprotective properties. The lead asset targets multiple oncology indications including acute myeloid leukemia (AML), EGFR-mutated non-small cell lung cancer (NSCLC), and solid tumours in combination with doxorubicin, through Phase 1, Phase 1a/b, and Phase 3 clinical programs.

Product overview

Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as a targeted cancer therapy with unique cardioprotective properties. The company's product portfolio centers on RC220 as the lead asset, which is being advanced through multiple clinical programs: Phase 3 in acute myeloid leukemia (EMILI-3), Phase 1a/b in EGFR-mutated non-small cell lung cancer (HARNESS-1), and Phase 1 in solid tumours in combination with doxorubicin (CPACS). The company also maintains the original bisantrene formulation (RC110) with published Phase 2 clinical data. All formulations leverage the drug's mechanism of action involving G4-DNA and RNA binding to silence the MYC cancer growth regulator.

Differentiator

Problem solved

Functional benefit

Products and services

  • RC220 Proprietary reformulated version of (E,E)-bisantrene designed to enable peripheral and central intravenous administration while maintaining pharmacokinetics and anticancer activity. Lead drug candidate with dual anticancer and cardioprotective properties for AML, EGFRm NSCLC, and solid tumours in combination with doxorubicin.
  • Cardioprotection Blood Test Novel blood-based molecular test designed to assess the cardioprotective effects of lead drug candidate RC220 in cancer patients undergoing chemotherapy.

Quantifiable outcome

  • 46% complete response rate in relapsed/refractory AML across 10 monotherapy studies with 146 patients
  • +3 more outcomes

Companies that use Racura Oncology

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Racura Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Racura Oncology partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • AstexcoreStrategic or Co-development PartnerCollaboration with Astex, a leading precision medicine company, as part of Racura's global scientific and medical partnerships network.
  • City of HopecoreStrategic or Co-development PartnerExclusive licensing agreement with City of Hope for bisantrene development. City of Hope is a renowned cancer research and treatment institution.
  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaboration with MD Anderson, one of the world's most respected cancer centers, as part of global partnerships to advance bisantrene.
  • Sheba City of HealthcoreStrategic or Co-development PartnerPartnership with Sheba Medical Center in Israel, where investigator-sponsored bisantrene trials in AML were conducted under Professor Arnon Nagler.
  • UNC School of MedicinecoreStrategic or Co-development PartnerCollaboration with University of North Carolina School of Medicine as part of Racura's global scientific and medical partnerships network.
  • University of WollongongcoreStrategic or Co-development PartnerAcademic partnership with University of Wollongong for bisantrene research and development. Professor Michael Kelso, VP of Research, is from this university.
  • University of NewcastlecoreStrategic or Co-development PartnerAcademic partnership with University of Newcastle as part of Racura's collaboration network for scientific research.
  • Ardena Holding NVcoreImplementation/ SI/ Consulting PartnerManufacturing partnership with Ardena Holding NV to provide additional current Good Manufacturing Practice (cGMP) manufacturing for bisantrene.
  • Purdue UniversitycoreStrategic or Co-development PartnerPartnership with Purdue University for molecular level studies on how (E,E)-bisantrene binds to the MYC-G4 DNA structure.
  • Emory UniversitycoreStrategic or Co-development PartnerCollaboration with Emory University as part of Racura's scientific partnerships network to advance understanding of bisantrene.
  • George ClinicalcoreImplementation/ SI/ Consulting PartnerContract Research Organisation (CRO) appointed to support the Phase 1a/1b trial for RC220 bisantrene in solid tumour patients.
  • Baker Heart and Diabetes InstituteminorStrategic or Co-development PartnerAssociate Professor Erin Howden from the Baker Heart and Diabetes Institute joined Racura's Scientific Advisory Board to provide expertise on cardiometabolic effects of chemotherapy.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Racura Oncology competitors and assessment

Company assessment

Regional players

  • Kazia Therapeutics: Australian clinical-stage oncology company developing small-molecule drugs for brain cancers and other solid tumors. Comparable as a small ASX-listed biotech with an oncology pipeline.
  • Imugene: Australian clinical-stage immuno-oncology company developing B-cell vaccines and oncolytic virotherapy. Comparable as a small ASX-listed oncology biotech advancing multiple clinical programs.
  • Opthea: Australia-based clinical-stage developer of oncology therapeutics. Geographic and stage peer to Racura, though Opthea focuses on ophthalmology-related VEGF therapies rather than cytotoxic chemotherapy.

Broad incumbents

  • AbbVie: Global pharmaceutical company with venetoclax (Venclexta), a leading AML therapy. Represents the established competitive standard-of-care that any new AML entrant must address.
  • Servier Pharmaceuticals: Global pharmaceutical company with significant AML franchise (Tibsovo, idhifa) and oncology pipeline. Represents the established competitive landscape in hematologic oncology.
  • Astellas Pharma: Global pharmaceutical company with established AML and oncology franchises, including gilteritinib. Sets the competitive bar for AML drug approvals and reimbursement.

Emerging players

  • Actinium Pharmaceuticals: US clinical-stage company developing targeted radiotherapies for AML and other hematologic malignancies. Comparable as a small-cap AML-focused developer at a similar clinical stage to Racura.
  • Cylene Pharmaceuticals: Developer of small molecules targeting G-quadruplex (G4) DNA structures and MYC oncogene regulation. Directly comparable to Racura's G4-DNA/MYC mechanism of action for (E,E)-bisantrene, though at a different stage of development.

Direct peers

  • Noxopharm: Australian clinical-stage oncology company developing small-molecule therapeutics. Comparable to Racura as a similarly small ASX-listed biotech pursuing oncology indications with limited commercial revenue.
  • Cyclacel Pharmaceuticals: Clinical-stage oncology company developing small-molecule drugs with a primary focus on acute myeloid leukemia. Directly comparable to Racura's AML-led development strategy with RC220.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Racura Oncology social profiles

Digital presence

Racura Oncology compliance and trust

Trust signal

Compliance2 records

Racura Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Racura Oncology leadership team

Management profile

Number of profiles

Profiles9 records

Racura Oncology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Racura Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Racura Oncology

What does Racura Oncology do?

Racura Oncology is a clinical-stage biopharmaceutical company developing RC220, a proprietary reformulation of (E,E)-bisantrene, as an anticancer therapy with dual anticancer and cardioprotective properties. The lead asset targets multiple oncology indications including acute myeloid leukemia (AML), EGFR-mutated non-small cell lung cancer (NSCLC), and solid tumours in combination with doxorubicin, through Phase 1, Phase 1a/b, and Phase 3 clinical programs.

Is Racura Oncology a public or private company?

Racura Oncology is a public company. It is classified as public and is currently operating.

When was Racura Oncology founded?

Racura Oncology was founded in 2021. It employs 11 to 50 people.

Where is Racura Oncology based?

Racura Oncology is headquartered in Sydney, Australia, in the Oceania region.

How does Racura Oncology make money?

One revenue line is on record: drug Development & Commercialization.

Who are Racura Oncology's main competitors?

Regional players on record are Kazia Therapeutics, Imugene and Opthea. Broad incumbents are AbbVie, Servier Pharmaceuticals and Astellas Pharma. Emerging players are Actinium Pharmaceuticals and Cylene Pharmaceuticals. Direct peers are Noxopharm and Cyclacel Pharmaceuticals.

Does Racura Oncology have an API?

No public API is recorded for Racura Oncology.

What industry is Racura Oncology in?

Racura Oncology's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewRacura Oncology Demonstrates Key Equivalence for Reformulated Bisantrene Anti-Cancer DrugRacura Oncology reported that its reformulated bisantrene drug RC220 showed pharmacokinetic equivalence to the older RC110 formulation in a canine study. Peak and total exposure ratios fell within the 0.80–1.25 equivalence range, supporting use of RC110 clinical data for RC220's Phase 2b/3 EMILI trial in AML.AInvestRacura Oncology Funds Itself With Piggyback Options. Its AGM Deadline Is the Only Lever Shareholders HaveRacura Oncology set its AGM for 23 November 2026, with a director-nomination deadline as the only shareholder lever. In June, holders exercised 97% of bonus options, raising A$24.4 million to fund Phase 3 trials. The cycle repeats as the board sets next terms.KalkineThe Under-the-Radar Cancer Stock Lighting Up the Forums — Is Racura the Next Biotech Breakout?Racura Oncology, formerly Race Oncology, is advancing its lead program RC220 into early-phase clinical trials. The company develops bisantrene, a drug with potential anti-cancer activity and protection against chemotherapy-induced cardiotoxicity. As a pre-revenue, cash-burning biotech, it faces high attrition and dilution risks.KalkineRacura Oncology (ASX:RAC) in Focus as Investors Track Precision Medicine ProgressRacura Oncology Limited (ASX:RAC) shares declined 1.97% to AUD 1.99 on 7 August 2026 during a trading session marked by weakness across the Australian healthcare sector. The S&P/ASX 200 Health Care index fell 0.73% to 28,029.60 during the same session. The company operates in the biotechnology sector focusing on oncology-related therapeutic research and development.Clinical Trials ArenaFirst patient dosed in Racura’s HARNESS-1 trial of RC220Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial for RC220 in combination with osimertinib, targeting EGFR-mutant non-small cell lung cancer (NSCLC). This milestone aims to address the challenge of therapeutic resistance faced by patients with EGFR-mutant NSCLC. The trial will assess the safety, pharmacodynamics, and clinical activity of RC220 in this context.AijournRacura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung CancerRacura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer, with the patient receiving RC220 at 50 mg/m2 intravenously with no adverse events observed. The trial aims to assess whether targeting G4-DNA and RNA structures can delay or prevent EGFR tyrosine kinase inhibitor treatment resistance, enrolling 12 to 40 patients in dose-escalation before advancing to a 40-patient Phase 1b expansion stage. The company is exploring this combination as a potential new therapeutic strategy for patients who currently have limited options once resistance develops.PR Newswire APACRacura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung CancerRacura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b clinical trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer at Monash Health in Victoria, Australia. RC220 is a proprietary formulation of (E,E)-bisantrene designed to target G-quadruplex DNA and RNA structures to address tyrosine kinase inhibitor resistance. The dose-escalation stage will enroll 12 to 40 patients across three initial single-patient cohorts at 50 mg/m2, 100 mg/m2 and 150 mg/m2, followed by a Phase 1b expansion stage with 40 patients receiving one of two dose levels.PharmaTimesRacura treats first patient in phase 1 HARNESS‑1 lung cancer trialRacura Oncology treated the first patient in its phase 1 HARNESS‑1 trial of RC220 for EGFR‑mutant NSCLC, administering 50mg/m² with no adverse events. The study assesses RC220 combined with osimertinib, using single‑patient cohorts for dose escalation up to 150mg/m². The trial expects 12–40 participants in dose escalation and 40 in a phase 1b expansion.BioSpaceRacura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung CancerRacura Oncology dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 with osimertinib for EGFR-mutant NSCLC. The first patient received 50 mg/m2 IV with no adverse events. The trial aims to delay TKI resistance, with dose escalation and expansion planned.